Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...